575 related articles for article (PubMed ID: 29065110)
1. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher AH; Brown MP
Br J Cancer; 2017 Dec; 117(12):1736-1742. PubMed ID: 29065110
[TBL] [Abstract][Full Text] [Related]
2. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
Singh AP; Sharma S; Shah DK
J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
[TBL] [Abstract][Full Text] [Related]
3. Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.
Xu S
Pharm Res; 2015 Nov; 32(11):3577-83. PubMed ID: 26108878
[TBL] [Abstract][Full Text] [Related]
4. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
5. Cell killing by antibody-drug conjugates.
Kovtun YV; Goldmacher VS
Cancer Lett; 2007 Oct; 255(2):232-40. PubMed ID: 17553616
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates in tumor therapy.
Sammet B; Steinkühler C; Sewald N
Pharm Pat Anal; 2012 Mar; 1(1):65-73. PubMed ID: 24236714
[TBL] [Abstract][Full Text] [Related]
7. APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective
Staudacher AH; Li Y; Liapis V; Hou JJC; Chin D; Dolezal O; Adams TE; van Berkel PH; Brown MP
Mol Cancer Ther; 2019 Feb; 18(2):335-345. PubMed ID: 30413648
[TBL] [Abstract][Full Text] [Related]
8. Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate.
Mohamed Amar IA; Huvelle S; Douez E; Letast S; Henrion S; Viaud-Massuard MC; Aubrey N; Allard-Vannier E; Joubert N; Denevault-Sabourin C
Eur J Med Chem; 2022 Feb; 229():114063. PubMed ID: 34974337
[TBL] [Abstract][Full Text] [Related]
9. Trends in cancer-targeted antibody-drug conjugates.
Bidard FC; Trédan O
Target Oncol; 2014 Mar; 9(1):1-8. PubMed ID: 24221961
[TBL] [Abstract][Full Text] [Related]
10. Marine Antibody-Drug Conjugates: Design Strategies and Research Progress.
Wang YJ; Li YY; Liu XY; Lu XL; Cao X; Jiao BH
Mar Drugs; 2017 Jan; 15(1):. PubMed ID: 28098746
[TBL] [Abstract][Full Text] [Related]
11. Extracellular vesicles as modifiers of antibody-drug conjugate efficacy.
Barok M; Puhka M; Yazdi N; Joensuu H
J Extracell Vesicles; 2021 Feb; 10(4):e12070. PubMed ID: 33613875
[TBL] [Abstract][Full Text] [Related]
12. A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.
Singh AP; Shah DK
J Pharm Sci; 2019 Jul; 108(7):2465-2475. PubMed ID: 30790581
[TBL] [Abstract][Full Text] [Related]
13. Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.
Ekholm FS; Pynnönen H; Vilkman A; Pitkänen V; Helin J; Saarinen J; Satomaa T
ChemMedChem; 2016 Nov; 11(22):2501-2505. PubMed ID: 27786414
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
15. Bystander effect of antibody-drug conjugates: fact or fiction?
Giugliano F; Corti C; Tarantino P; Michelini F; Curigliano G
Curr Oncol Rep; 2022 Jul; 24(7):809-817. PubMed ID: 35305211
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
Papachristos A; Pippa N; Demetzos C; Sivolapenko G
Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
18. ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs).
Beaumont K; Pike A; Davies M; Savoca A; Vasalou C; Harlfinger S; Ramsden D; Ferguson D; Hariparsad N; Jones O; McGinnity D
Xenobiotica; 2022 Aug; 52(8):770-785. PubMed ID: 36314242
[TBL] [Abstract][Full Text] [Related]
19. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
Lu J; Jiang F; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329
[TBL] [Abstract][Full Text] [Related]
20. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
